A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
An Open-Label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Jenny Li
- Telefoonnummer: 650-237-9339
- E-mail: clinicaltrials@miracogen.com.cn
Studie Contact Back-up
- Naam: Leanne Drummond, Bachelor
- Telefoonnummer: 984-208-9519
- E-mail: leanne.drummond@worldwide.com
Studie Locaties
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Hunan Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 201321
- Fudan University Shanghai Cancer Center
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- The First Affiliated Hospital, College of Medicine, Zhejiang University
-
-
-
-
California
-
Orange, California, Verenigde Staten, 92868-3201
- Chao Family Comprehensive Cancer Center
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering 60th Street Outpatient Center
-
-
Ohio
-
Canton, Ohio, Verenigde Staten, 44718
- Gabrail Cancer Center Research
-
Cincinnati, Ohio, Verenigde Staten, 45219
- The Christ Hospital Cancer Center
-
-
Pennsylvania
-
Gettysburg, Pennsylvania, Verenigde Staten, 17325
- Gettysburg Cancer Center
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Virginia Cancer Specialists
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Understands and provides written informed consent and willing to follow the requirements specified in protocol.
- Age ≥18 years.
- Life expectancy ≥6 months.
- For Part B patients, documented Tissue Factor (TF) presence in tumor biopsy specimens obtained from archival or re-biopsy specimens by immunohistochemistry (IHC) protein expression.
- Must have histologically or cytologically confirmed unresectable or metastatic cancer with documented disease progression during prior therapy, or relapse or progression following approved standard therapy for their tumor types- Part A and Part B.
- Part B: Patients who have documented progression during or relapse following standard therapy, no further treatment options that are known to improve survival, and participation in a clinical trial is a reasonable therapeutic option.
- Patients must have measurable disease per RECIST v1.1.
- ECOG performance status of 0 or 1.
- Acceptable bone marrow, hepatic, cardiac, renal, and coagulation function.
- A negative serum pregnancy test if female and aged between 18-55 years old.
- Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for 180 days after the last infusion of MRG004A.
Exclusion Criteria:
- Archival or biopsy tumor shows TF IHC membrane or cytosolic score of zero, no TF-positive expression or no TF-positive staining in Part B patients.
- Toxicities (except alopecia & fatigue) due to prior antitumor therapy are greater than CTCAE v5.0 Grade 1.
- Toxicities due to prior radiotherapy that have not resolved to Grade ≤ 1 CTCAE v5.0 at least 21 days prior to the first treatment.
- Untreated, unstable or uncontrolled central nervous system (CNS) metastases.
- Any other type of anti-cancer therapy within 21 days of the first dose of study treatment. Use of any other type of anti-cancer treatment is prohibited throughout the study.
- Patients with increased bleeding risk.
- Presence of severe cardiac dysfunction.
- Pulmonary embolism or deep vein thrombosis within 3 months prior to the first dose of study drug.
- Concurrent malignancy within 5 years prior to entry.
- Uncontrolled or poorly controlled hypertension.
- History of ventricular tachycardia, or torsade des pointes.
- History of moderate to severe dyspnea at rest.
- Major surgery within 4 weeks of the first dose of study treatment and not fully recovered. Minor surgery within 2 weeks prior to study treatment.
- Known allergic reactions to any component or excipient of MRG004A or known allergic reactions to other prior anti-TF (including investigational) or other monoclonal antibody ≥ Grade 3.
- Patients who have any known liver disease, including chronic hepatitis B, hepatitis C, autoimmune hepatic disorders, primary biliary cirrhosis or sclerosing cholangitis; Patients who have concurrent, serious, uncontrolled infections or known infection with HIV, or have a diagnosed acquired immunodeficiency syndrome (AIDS); or an uncontrolled autoimmune disease, or have undergone organ transplant.
- Active uncontrolled bacterial, viral, fungal, rickettsial, or parasitic infection.
- Use of systemic corticosteroids within 4 weeks prior to the first dose of treatment.
- Use of strong CYP3A4 inhibitors or inducers with MRG004A.
- Other excluded medications or treatment: therapeutic anti-coagulative, or long-term anti-platelet treatment; multivitamins, calcium, vitamin D, and prophylactic anti-RANKL (denosumab) and zoledronic acid therapies for bone metastases are allowed.
- Any patient with a positive pregnancy or is breast-feeding.
- Any severe and/or uncontrolled systemic disease that at the discretion of investigator and sponsor makes it undesirable for the patient to participate in this study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: MRG004A
All patients in Part A (dose escalation) and Part B (dose expansion) will be administrated MRG004A on Day 1 of every 3 weeks (21-day cycle).
|
Administrated intravenously
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
Tijdsspanne: DLT will be evaluated during the first treatment cycle (Day 1-21)
|
The highest dose confirmed wherein less than 2 out of 6, or < 33% of evaluable patients in a treatment cohort experiences dose-limiting toxicity (DLT).
|
DLT will be evaluated during the first treatment cycle (Day 1-21)
|
|
Recommended Phase II Dose (RP2D)
Tijdsspanne: Baseline to study completion (up to 24 months)
|
The dose level of MRG004A recommended for further clinical studies based on assessment of the safety, efficacy and PK data from Part A of this study.
|
Baseline to study completion (up to 24 months)
|
|
Objective Response Rate (ORR)
Tijdsspanne: Baseline to study completion (up to 24 months)
|
The proportion of patients who achieve complete response (CR) or partial response (PR) as assessed by the Independent Central Review (ICR).
|
Baseline to study completion (up to 24 months)
|
|
Adverse Events (AEs)
Tijdsspanne: From signing informed consent until 45 days after the last dose of MRG004A
|
Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.
|
From signing informed consent until 45 days after the last dose of MRG004A
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Duur van de respons (DOR)
Tijdsspanne: Basislijn om voltooiing te bestuderen (tot 24 maanden)
|
Het tijdsinterval tussen de datum van de vroegste kwalificatierespons en de datum van ziekteprogressie of overlijden voor welke oorzaak dan ook, afhankelijk van wat zich eerder voordoet.
|
Basislijn om voltooiing te bestuderen (tot 24 maanden)
|
|
Disease Control Rate (DCR)
Tijdsspanne: Baseline to study completion (up to 24 months)
|
The proportion of patients who achieve CR, PR, or stable disease (SD) ≥ 6 weeks based on RECIST v1.1.
|
Baseline to study completion (up to 24 months)
|
|
Progression Free Survival (PFS)
Tijdsspanne: Baseline to study completion (up to 24 months)
|
The time from the date of first study dose to disease progression or death whichever occurs first.
|
Baseline to study completion (up to 24 months)
|
|
Overall Survive (OS)
Tijdsspanne: Baseline to study completion (up to 24 months)
|
The time from start of study treatment to date of death as a result of any cause.
|
Baseline to study completion (up to 24 months)
|
|
Pharmacokinetics (PK) Parameter of MRG004A: Cmax
Tijdsspanne: Baseline to 30 days after the last dose of study treatment
|
Maximum observed plasma concentration.
|
Baseline to 30 days after the last dose of study treatment
|
|
Pharmacokinetics (PK) Parameter of MRG004A: Tmax
Tijdsspanne: Baseline to 30 days after the last dose of study treatment
|
Time to reach the maximum plasma concentration.
|
Baseline to 30 days after the last dose of study treatment
|
|
Pharmacokinetics (PK) Parameter of MRG004A: AUClast
Tijdsspanne: Baseline to 30 days after the last dose of study treatment
|
Area under the plasma concentration-time curve from time 0 to the time of last quantifiable concentration.
|
Baseline to 30 days after the last dose of study treatment
|
|
Incidentie van anti-drug antilichaam (ADA)
Tijdsspanne: Basislijn tot 30 dagen na de laatste dosis studiebehandeling
|
Het percentage patiënten met positieve ADA-immunogeniciteitsresultaten.
|
Basislijn tot 30 dagen na de laatste dosis studiebehandeling
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Nashat Y Gabrail, MD, Gabrail Cancer Center Research
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Werkelijk)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- MRG004A-001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .